Maria Zhadina1, Kelly L Roszko1, Raya E S Geels2, Luis F de Castro1, Michael T Collins1, Alison M Boyce1,3. 1. Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA. 2. Department of Medicine, Division of Endocrinology, Centre for Bone Quality, Leiden University Medical Centre, ZA Leiden, the Netherlands. 3. Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland , USA.
Abstract
CONTEXT: Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is a rare bone and endocrine disorder resulting in fractures, pain, and disability. There are no targeted or effective therapies to alter the disease course. Disease arises from somatic gain-of-function variants at the R201 codon in GNAS, replacing arginine by either cysteine or histidine. The relative pathogenicity of these variants is not fully understood. OBJECTIVE: This work aimed 1) to determine whether the most common GNAS variants (R201C and R201H) are associated with a specific clinical phenotype, and 2) to determine the prevalence of the most common GNAS variants in a large patient cohort. METHODS: This retrospective cross-sectional analysis measured the correlation between genotype and phenotype characterized by clinical, biochemical, and radiographic data. RESULTS: Sixty-one individuals were genotyped using DNA extracted from tissue or circulating cell-free DNA. Twenty-two patients (36.1%) had the R201C variant, and 39 (63.9%) had the R201H variant. FD skeletal disease burden, hypophosphatemia prevalence, fracture incidence, and ambulation status were similar between the 2 groups. There was no difference in the prevalence of endocrinopathies, ultrasonographic gonadal or thyroid abnormalities, or pancreatic involvement. There was a nonsignificant association of cancer with the R201H variant. CONCLUSION: There is no clear genotype-phenotype correlation in patients with the most common FD/MAS pathogenic variants. The predominance of the R201H variant observed in our cohort and reported in the literature indicates it is likely responsible for a larger burden of disease in the overall population of patients with FD/MAS, which may have important implications for the future development of targeted therapies. Published by Oxford University Press on behalf of the Endocrine Society 2021.
CONTEXT: Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is a rare bone and endocrine disorder resulting in fractures, pain, and disability. There are no targeted or effective therapies to alter the disease course. Disease arises from somatic gain-of-function variants at the R201 codon in GNAS, replacing arginine by either cysteine or histidine. The relative pathogenicity of these variants is not fully understood. OBJECTIVE: This work aimed 1) to determine whether the most common GNAS variants (R201C and R201H) are associated with a specific clinical phenotype, and 2) to determine the prevalence of the most common GNAS variants in a large patient cohort. METHODS: This retrospective cross-sectional analysis measured the correlation between genotype and phenotype characterized by clinical, biochemical, and radiographic data. RESULTS: Sixty-one individuals were genotyped using DNA extracted from tissue or circulating cell-free DNA. Twenty-two patients (36.1%) had the R201C variant, and 39 (63.9%) had the R201H variant. FD skeletal disease burden, hypophosphatemia prevalence, fracture incidence, and ambulation status were similar between the 2 groups. There was no difference in the prevalence of endocrinopathies, ultrasonographic gonadal or thyroid abnormalities, or pancreatic involvement. There was a nonsignificant association of cancer with the R201H variant. CONCLUSION: There is no clear genotype-phenotype correlation in patients with the most common FD/MAS pathogenic variants. The predominance of the R201H variant observed in our cohort and reported in the literature indicates it is likely responsible for a larger burden of disease in the overall population of patients with FD/MAS, which may have important implications for the future development of targeted therapies. Published by Oxford University Press on behalf of the Endocrine Society 2021.
Entities:
Keywords:
G-coupled protein receptors; cell free DNA; metabolic bone disease
Authors: Francesco S Celi; Giuseppe Coppotelli; Aaron Chidakel; Marilyn Kelly; Beth A Brillante; Thomas Shawker; Natasha Cherman; Penelope P Feuillan; Michael T Collins Journal: J Clin Endocrinol Metab Date: 2008-03-18 Impact factor: 5.958
Authors: M Hagelstein-Rotman; M E Meier; B C J Majoor; A H G Cleven; P D S Dijkstra; N A T Hamdy; M A J van de Sande; O M Dekkers; N M Appelman-Dijkstra Journal: Calcif Tissue Int Date: 2020-11-23 Impact factor: 4.333
Authors: Michael T Collins; Nicholas J Sarlis; Maria J Merino; Jason Monroe; Susan E Crawford; Jonathan A Krakoff; Lori C Guthrie; Sandra Bonat; Pamela G Robey; Andrew Shenker Journal: J Clin Endocrinol Metab Date: 2003-09 Impact factor: 5.958
Authors: Alison M Boyce; William H Chong; Thomas H Shawker; Peter A Pinto; W Marsten Linehan; Nisan Bhattacharryya; Maria J Merino; Frederick R Singer; Michael T Collins Journal: J Clin Endocrinol Metab Date: 2012-06-28 Impact factor: 5.958
Authors: Raya E S Geels; Maartje E Meier; Amanda Saikali; Roula Tsonaka; Natasha M Appelman-Dijkstra; Alison M Boyce Journal: J Bone Miner Res Date: 2021-11-17 Impact factor: 6.390